| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.047 | 0.4 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.067 | 0.4 |